Skip to main content

Fecal Pills

A study shows that fecal transplants in an oral capsule form are an effective treatment for Clostridium difficile infection.

Written byAbby Olena, PhD
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

PUBLIC HEALTH IMAGE LIBRARY, CDCClostridium difficile (C. diff) infection can cause severe diarrhea and cramping, often leading to hospitalization. Transplantation of donor feces containing normal gut bacteria via enema, colonscopy, or nose tube has been shown to be an effective treatment for this often recurring infection. But a report presented this month (October 3) at IDWeek 2013, an international meeting of infectious disease specialists in San Francisco, has shown that less off-putting oral fecal capsules also work.

A University of Calgary group, let by physician Thomas Louie, used centrifugation to collect sediment containing beneficial microbes from feces of healthy donors (usually patient relatives) and then packaged the sediment in gelatin capsules. Patients who had experienced at least three severe C. diff infections took one dose of two to three dozen fecal pills over about 15 minutes on an empty stomach. None of the 27 patients who received the treatment in 2010 has since relapsed.

“The approach that Dr. Louie has is completely novel—no one else has done this,” Curtis Donskey, an associate professor of medicine at Case Western Reserve University in Cleveland and a physician the Cleveland Veterans Affairs Medical Center, told the Associated Press. “I am optimistic that this type of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo